Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer

被引：0
|
作者：
Jiang, M. [1 ]
Chai, Y. [1 ]
Liu, J. [2 ]
He, M. [1 ]
Zhang, M. [1 ]
Zhou, S. [1 ]
Xu, B. [3 ]
Li, Q. [2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Med Oncol, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.270
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331P
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA
    Li, H.
    Guan, X.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Li, K.
    Liu, C.
    Chu, Y.
    Ma, A.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [32] Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA)
    Schneeweiss, A.
    Chia, S.
    Hickish, T.
    Harvey, V.
    Hegg, R.
    Tausch, C.
    Seo, J. H.
    Tsai, Y. F.
    McNally, V.
    Cortes, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
  • [33] Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
    Heidy Cedeño
    Rafael Araúz
    Fernando Cebamanos
    Idalmis de Torraza
    Ana Porcell
    BMC Cancer, 7 (Suppl 1)
  • [34] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [35] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [36] Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
    Semiglazov, V.
    Eiermann, W.
    Zambetti, M.
    Manikhas, A.
    Bozhok, A.
    Lluch, A.
    Tjulandin, S.
    Sabadell, M. D.
    Caballero, A.
    Valagussa, P.
    Baselga, J.
    Gianni, L.
    EJSO, 2011, 37 (10): : 856 - 863
  • [37] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [38] The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Leon-Ferre, Roberto A.
    Hieken, Tina J.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 2111 - 2119
  • [39] Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Chantada-Vazquez, Maria del Pilar
    Conde-Amboage, Mercedes
    Grana-Lopez, Lucia
    Vazquez-Estevez, Sergio
    Bravo, Susana B.
    Nunez, Cristina
    CANCERS, 2022, 14 (04)
  • [40] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345